Product Description:

 

• Product Name: Voriconazole

• Drug Classification: Antifungal agent

• Strength: 20 mg

• Product Form: Tablets

• Packing Specifications: 10’s

• Pharmacokinetics:

Voriconazole exhibits excellent oral bioavailability, reaching peak plasma concentrations within 2 hours post-administration. The drug undergoes extensive hepatic metabolism, primarily mediated by cytochrome P450 enzymes, notably CYP2C19 and CYP3A4. Metabolites are excreted in urine and feces, with an elimination half-life ranging from 6 to 12 hours, allowing for convenient dosing schedules.

 

Pharmacodynamics:

 

As a potent triazole antifungal agent, Voriconazole inhibits ergosterol synthesis, a vital component of fungal cell membranes. By disrupting membrane integrity, Voriconazole exerts fungicidal activity against a wide spectrum of fungi, including Candida spp. and Aspergillus spp., among others.

 

Formulations:

Tablets: Each tablet contains 20 mg of Voriconazole, providing a convenient oral formulation for the treatment of fungal infections.

 

Indications:

Voriconazole is indicated for the treatment of various fungal infections, including:

 

• Invasive aspergillosis

• Candidemia in non-neutropenic patients

• Disseminated Candida infections

• Esophageal candidiasis

• Serious fungal infections caused by Scedosporium spp. and Fusarium spp.

 

Usage:

Voriconazole should be administered under the supervision of a healthcare professional experienced in managing fungal infections. The dosage and duration of treatment may vary based on the type and severity of the infection, as well as the patient’s renal function and clinical status.

 

Dosage:

The recommended dosage of Voriconazole for the treatment of invasive fungal infections typically ranges from 200 to 400 mg orally or intravenously every 12 hours. Dosage adjustments may be necessary for patients with hepatic impairment or renal dysfunction.

 

Side Effects:

Common side effects associated with Voriconazole therapy may include:

 

• Visual disturbances, such as blurred vision, photophobia, and color vision changes
• Gastrointestinal symptoms, including nausea, vomiting, diarrhea, and abdominal pain
• Hepatic abnormalities, such as elevated liver enzymes and hepatic dysfunction
• Skin reactions, such as rash, pruritus, and photosensitivity
• Serious adverse reactions, including hepatotoxicity, QT prolongation, and hypersensitivity reactions, may occur rarely and require immediate medical attention.

 

At AIT Pharmaceuticals Division, we are committed to improving patient outcomes through innovative pharmaceutical solutions. For further information or assistance, please consult your healthcare provider or pharmacist.

 

Always read the label and follow the instructions for use.